Dyskinesias and Neural Grafting in Parkinson's Disease

摘要: In the past 20 years, intracerebral transplantation of embryonic ventral mesencephalic (VM) tissue has been looked upon as a particularly promising approach for treatment Parkinson’s disease (PD). Among many possible options future, bore promise truly curative approach: endogeneous, degenerating dopamine (DA) neurons would be substituted by healthy DA-producing cells, restoring damaged nigrostriatal circuit once and all (Nikkhah Brandis, 1995; Barker, 2000; Fricker-Gates et al., 2001). Hopes were fostered encouraging results produced intrastriatal VM transplants both in animal models PD (Bjorklund, 1992; Bjorklund Stenevi, 1979; Herman Abrous, 1994; Perlow 1979) early openlabel clinical trials (Lindvall, Lindvall Hagell, 2000 Chapter 5). The latter showed that can engraft parkinsonian striatum provide local source DA storage release. majority transplanted patients grafts found to ameliorate symptoms reduce need L-DOPA pharmacotherapy (Lindvall 2000). addition their immediate implications PD, these also suggested neural cell replacement could develop into radically new wide range neurological disorders (Gage 1988; Bjorklund, Aichner 2002; Turner Shetty, 2003; Grisolia, Peschansky Dunnett, Studer 1998). This enthusiasm was dampened alarming reports from first NIH-sponsored